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Abstract
T cells genetically modified to express a CD19-specific chimeric antigen receptor (CAR) for the 
investigational treatment of B-cell malignancies comprise a heterogeneous population, and their 
ability to persist and participate in serial killing of tumor cells is a predictor of therapeutic success. 
We implemented Timelapse Imaging Microscopy In Nanowell Grids (TIMING) to provide direct 
evidence that CD4+CAR+ T cells (CAR4 cells) can engage in multi-killing via simultaneous 
conjugation to multiple tumor cells. Comparisons of the CAR4 cells and CD8+CAR+ T cells 
(CAR8 cells) demonstrate that while CAR4 cells can participate in killing and multi-killing, they 
do so at slower rates, likely due to the lower Granzyme B content. Significantly, in both sets of T 
cells, a minor sub-population of individual T cells identified by their high motility, demonstrated 
efficient killing of single tumor cells. By comparing both the multi-killer and single killer CAR+ T 
cells it appears that the propensity and kinetics of T-cell apoptosis was modulated by the number 
of functional conjugations. T cells underwent rapid apoptosis, and at higher frequencies, when 
conjugated to single tumor cells in isolation and this effect was more pronounced on CAR8 cells. 
Our results suggest that the ability of CAR+ T cells to participate in multi-killing should be 
evaluated in the context of their ability to resist activation induced cell death (AICD). We 
anticipate that TIMING may be utilized to rapidly determine the potency of T-cell populations and 
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may facilitate the design and manufacture of next-generation CAR+ T cells with improved 
efficacy.
INTRODUCTION
Chimeric antigen receptors (CARs, glossary of abbreviations in supplementary information) 
are hybrid molecules that typically combine the specificity and affinity of single-chain 
antibodies with selected intracellular signaling domains of the T-cell receptor (TCR) 
complex1-3. When expressed on genetically modified T cells, CARs redirect specificity 
independent of human leukocyte antigen (HLA) to recognize tumor-associated antigens 
(TAAs). Second and third generation CARs include the endodomains for co-stimulatory 
molecules and can thus directly endow the different signals needed for T-cell activation 
upon binding TAA4. Initial data from clinical trials at multiple centers reporting the adoptive 
transfer of T cells genetically modified to express a CD19-specific CAR for the treatment of 
B-cell malignancies are encouraging, with patients benefiting from complete remissions5-7. 
These clinical results have accelerated the clinical translation of T cells bearing CARs 
targeting TAAs other than CD19 for the treatment of hematologic malignancies as well as 
solid tumors8-10. As a group, these clinical trials differ in the design and specificity of the 
CARs, the ex vivo approach used to manufacture the T cells, the in vivo regimen used to pre-
treat the recipient, the tumor burden and type, and the T-cell dosing scheme. Thus, drawing 
conclusions regarding the relative anti-tumor effects between the populations of 
bioengineered CAR+ T cells is not readily feasible1. One of the hallmarks of a 
therapeutically successful infusion is the presence of CAR+ T cells that can persist to 
execute multiple tumor cells within the tumor microenvironment11.
In spite of the recent success of adoptive immunotherapy, the mechanistic basis for the 
potency of a given T-cell product has not been well defined. The majority of adoptive 
studies have focused on infusing CD8+ T-cell populations because of their ability to directly 
recognize and lyse tumor cells, thus mediating antitumor immunity12. In the absence of 
CD4+ T-cell help however, some infused CD8+ T cells can become functionally 
unresponsive and undergo apoptosis13. Indeed, adoptive cell therapy (ACT) protocols that 
incorporate CD4+ T cells may mediate superior responses, and preclinical and clinical data 
have established the importance of CD4+ T-cell help during immunotherapy14,15. More 
recently however, adoptive transfer of CD4+ T-cell populations has shown that these cells 
can mediate regression of established melanoma, and that these cells can differentiate into 
cytolytic effectors16-18. Despite these advances direct comparisons of the potency and 
kinetics of interactions between donor-derived populations of CD4+ T cells and tumor cells 
at single-cell resolution, and the comparison to CD8+ T cells is lacking.
Although two-photon microscopy studies are well suited for understanding the mechanistic 
basis of T-cell tumor cell interactions in vivo, direct observation of killing and motility is 
restricted to tens of events that may lead to sampling bias. Additionally, these studies are 
limited in throughput and cannot be used to routinely determine the interactions between 
cellular infusions and tumor cells. In vitro dynamic imaging19-24 systems are well-suited for 
studying the longitudinal interactions between cells at single-cell resolution, in a defined 
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environment. Here, we have employed Timelapse Imaging Microscopy In Nanowell Grids 
(TIMING) to analyze the longitudinal interactions between individual CD19-specific T cells 
(effectors, E) expressing a second generation CAR with one or more CD19+ tumor cells 
(target(s), T). To the best of our knowledge, we demonstrate for the first time that 
CD4+CAR+ T cells (CAR4 cells) can directly engage in multi-killing via simultaneous 
conjugation to multiple tumor cells. The major differences between CAR4 and CD8+ CAR+ 
T cells (CAR8 cells), at the single-cell, in mediating tumor-cell lysis in vitro, was the 
kinetics of killing, and this was attributed to the differences in their intracellular Granzyme 
B (GzB) content. Surprisingly, in both sets of T cells, a minor sub-population of individual 
T cells identified by their high motility, demonstrated efficient killing of single tumor cells. 
By comparing both the multi-killer and single killer CAR+ T cells it appears that the 
propensity and kinetics of T-cell apoptosis was modulated by the number of functional 
conjugations. Our results demonstrate that the ability of CAR+ T cells to participate in multi-
killing should be evaluated in the context of their ability to resist AICD.
METHODS
Human Subjects Statement
All work outlined in this report was performed according to protocols approved by the 
Institutional Review Boards at the University of Houston and the University of Texas M.D. 
Anderson Cancer Center.
Cell Lines and antibodies
All antibodies were purchased from Biolegend (San Diego, CA). Human pre-B cell line 
NALM-6 (ATCC), Daudi-β2m (ATCC), T-cell lymphoma EL-4 (ATCC) and modified 
CD19+EL-4 cells were cultured as described previously25,26. The cell lines were routinely 
tested to ensure that they were free of mycoplasma contamination and flow-cytometry was 
utilized to confirm the expression of CD19.
Genetic modification and propagation of cells
PBMC from healthy volunteers were electroporated using Nucleofector II (Amaxa/Lonza) 
with DNA plasmids encoding for second generation CAR (designated CD19RCD28) and 
SB11 transposase and co-cultured with γ-irradiated K562 aAPC (clone 4) for 28 days along 
with cytokines (IL-2 and IL-21) in a 7-day stimulation cycle as described previously25. For 
single cell analysis, frozen CAR+ T cells were revived and re-stimulated with irradiated 
K562 aAPC before using them in experiments.
Flow cytometry
Cells were stained for cell surface markers (CAR, CD4, CD8, CD3), fixed and 
permeabilized (Cytofix/Cytoperm, BD Biosciences) for 20 min at 4°C. Cells were 
subsequently stained for intracellular granzyme B in perm/wash buffer at 4°C for 30 min, 
acquired on a FACS Calibur, and analyzed using FCS Express/FlowJo as previously 
described25. Statistical analyses for determining GzB expression were performed within R.
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End-point cytotoxicity assay
Nanowell array fabrication and the corresponding cytotoxicity assay to interrogate effector-
target interaction at single-cell level were performed as described previously21. Briefly, 
CAR+ T cells labeled with 1 µM of red fluorescent dye, PKH26 (Sigma) and target cells 
labeled with 1 µM of green fluorescent dye PKH67 were co-loaded onto nanowell arrays at a 
concentration of 106 cells/mL. Images were acquired on a Carl Zeiss Axio Observer fitted 
with a Hamamatsu EM-CCD camera using a 10× 0.3 NA objective. Automated image 
acquisition of the entire chip was performed at 0 and 6 hour and apoptosis was identified by 
staining with AnnexinV conjugated to Alexa-647 (Life Technologies, Carlsbad, CA).
TIMING assays
Nanowell grids were fixed in position on a 60 mm petridish. The cells were labeled and 
loaded exactly as described for the end-point assay and imaged on a Zeiss Axio Observer 
using a 20× 0.45 NA objective. Images were acquired for 12-16 hours at intervals of 7-10 
minutes.
Statistical analysis
The test used to determine p-values are listed in the legend of each figure.
Flow Cytometry based cytotoxicity assay
CAR4 cells (1×106 cells) were incubated with CD19+ target cells (0.2×106 cells; Daudiβ2m, 
NALM-6, CD19EL-4) at E:T ratio of 5:1 in the presence or absence of 5mM EGTA in 24-
well plates in 5% CO2 at 37°C for 6 hours. Following incubation cells were stained for CD3 
(T cells) and CD19 (tumor targets), acquired on a FACS Calibur (BD Biosciences) and 
analyzed using FCS Express version 3.00.007(Thornhill, Canada).
SI Methods contains a description of the image segmentation and tracking algorithms.
RESULTS
Production and phenotype of CAR+ T cells
Genetically modified and propagated T cells were generated from the peripheral blood 
mononuclear cells (PBMC) of healthy volunteer donors derived using the Sleeping Beauty 
(SB) system27 to enforce expression of a second generation CD19-specific CAR (designated 
CD19RCD28) that activates T cells via a chimeric CD3 and CD28 endodomain (Figures 
1A). Subsequent to expansion, CAR+ T cells from two separate donors contained 
predominantly CD8+ T cells (Figure 1B). The approach to producing the CAR+ T cells 
mirrors our manufacture in compliance with current good manufacturing practice for human 
application (Figures S1 and S2).
The cytotoxic potential, specificity and multi-killing ability of individual CAR+ T cells
Donor-derived CAR+ T-cell populations were evaluated for their ability to lyse CD19+EL4 
target cells, by co-culture within nanowell grids (Figures 1C and S3). At an E:T of 1:1, 
averaged across both donors, 29% of single CAR+ T cells induced apoptosis of (number of 
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events, Ntotal = 4,048) CD19+EL4 cells within six hours, whereas they induced apoptosis of 
just 1% (Ntotal = 3,682) of CD19−EL4 cells in the same time frame. The >29-fold increase 
of lysis of CD19+ versus CD19− targets confirms TAA-specific lysis (Figure 1D, p-value 
<0.0001, Fisher’s 2x2 test). In parallel, a conventional 4-hour 51Chromium release assay 
(CRA) was performed at the same E:T ratio (1:1) and reported a similar overall magnitude 
of target cells killing (mean 14-fold increase of lysis of CD19+ versus CD19−EL4 cells), 
albeit without single-cell resolution (Figure 1D). The ability to redirect specificity to lyse 
human CD19+ tumor cells was confirmed using the pre-B cell line NALM-6 (Figure S4). 
When averaged across both donors, within six hours of observation, individual CAR+ T cells 
induced apoptosis in 34% (Ntotal = 3,503) of NALM-6 target cells at an E:T ratio of 1:1. 
Across all of the samples tested, single cell assay demonstrated a linear correlation to the 
CRA (Figure 1D, r2 = 0.84, p-value = 0.01). The ability of individual T cells to eliminate 
more than one target cell was quantified by analyzing nanowells containing multiple targets 
(Figure S5). Averaged across both donors, at an E:T ratio of 1:2, within six hours, 21% 
(Ntotal = 2,294) of single CAR+ T cells killed exactly one CD19+EL4 target-cell whereas 
23% killed both targets (Figure 1E). During this same timeframe, at an E:T ratio of 1:3, 
22% (Ntotal = 1,108) of single CAR+ T cells killed exactly one target, 22 % killed exactly 
two targets, and 9% killed all three targets (Figure 1E). Thus, within a defined observation 
window, the likelihood that an individual CAR+ T cell killed more than one tumor cell 
improved as the number of targets within the nanowell increased but this might simply 
reflect higher frequency of interactions at higher cell densities (Figure S6). These findings 
were also observed when substituting NALM-6 as target cells, albeit with diminished 
frequency of multi-killing after 6 hours of co-culture (Figure S7). In aggregate, these data 
demonstrate that the responses measured by the single-cell assay are consistent with the 
results of CRA, and that multi-killer CAR+ T cells (ability to lyse at least two targets) 
comprised 20% (Ntotal = 3,402) of the CAR+ T-cell population.
Motile CD8+ cytotoxic T cells are efficient killers with decreased potential for activation 
induced cell death (AICD)
In order to gain an improved mechanistic understanding on the interaction between 
individual CAR+ T cells and NALM-6 tumor cells, we developed and implemented 
TIMING (Figure S8). Six parameters describing T-cell intrinsic behavior motility (dWell) 
and aspect ratio of polarization (AR), conjugation (contact lasting >7 minutes, tSeek and 
tContact), and death (tDeath and tAICD) were computed to define each interacting pair of 
effector and tumor cell (Figure 2A-C). At an E:T of 1:1, 77 % (Ntotal = 268) of single 
CD8+CAR+ T cells (CAR8 cells) that made at least one conjugate were able to kill the 
engaged leukemia cell. In order to identify subgroups of T cells that exhibited different 
behavioral interactions with the tumor cells leading to subsequent killing, the time series 
data for each of three features, total duration of conjugation, dwell and AR, underwent 
hierarchical clustering (Figure S9)28. Three T-cell subgroups were described that 
collectively accounted for 70% of the single-killer CAR8 cells: S1 (14% [7-20%], range), 
low conjugation and high motility; S2 (49% [32-66%]), high conjugation and low motility; 
and S3 (21% [19-22 %]), low conjugation and low motility (Figure S9). The high-motility 
subgroup, S1, comprised predominantly of elongated T cells that had an initial “lag-phase” 
(tSeek 184±38 minutes, Mean±SEM), but formed stable conjugates (tContact 98±13 minutes) 
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prior to target apoptosis (tDeath 204±35 minutes) (Figures 2D-F and S10). Predominantly, 
these T cells exhibited a decrease in motility and increased circularization (Figure S11) 
during tumor-cell conjugation, detached after tumor-cell death, resumed normal migratory 
function and had only a low frequency of effector cells undergoing AICD (Figure S12, 
Movie M1). The representative cell in the dominant subgroup, S2, established conjugation 
quickly (tSeek 36±6 minutes), and displayed sustained conjugation (tContact 145±16 minutes) 
prior to killing (tDeath 158±18 minutes) (Figures 2E-F). The majority of these T cells did 
not detach or resume migratory function after tumor-cell lysis, retained a predominantly 
circular morphology, and continued to remain conjugated >10 hours, even subsequent to the 
death of the conjugated tumor-cell (Movie M2). Moreover, 88% of S2 effector cells 
underwent apoptosis within the first ten hours of observation (Figure S12). Finally, T cells 
in the S3 subgroup were rapid killers (tContact 84±8 minutes and tDeath 118±20 minutes) that 
arrested after conjugation but failed to resume migration after tumor-cell detachment/killing 
(Figure 2E-F and Movie M3). Although these S3 effectors detached from tumor-cells after 
delivering the lethal hit, 53% then underwent apoptosis (Figure S12). Taken together these 
results demonstrate that at an E:T ratio of 1:1, the dominant subgroup of cells, S2, identified 
by their lack of motility and early conjugation to tumor cell, underwent AICD. On the 
contrary, highly motile CAR8 cells, S1, detached efficiently and resumed exploration of the 
local microenvironment, indicating that the motility of CAR8 cells might help identify 
efficient killers with decreased propensity for AICD. The observation that the majority of 
the CAR8 cells (S2 subgroup) maintained extended contact even after the death of the tumor 
cell is consistent with investigations on HIV-specific CTLs29.
CAR8 cell motility at increased tumor-cell densities facilitates multiplexed killing
The efficacy of CAR+ T cells to eliminate tumor burden in excess of the number of effectors 
infused is due to their ability to persist and participate in serial killing11. To facilitate 
identification of multi-killers, we next profiled the interactions in nanowells containing a 
single CAR8 cell and 2 to 5 NALM-6 tumor cells (E:T 1:2-5). The frequency of CAR8 cells 
that were able to simultaneously conjugate to two or more tumor cells increased from 25% 
to 49% as the number of targets within the nanowell increased, indicating that multiplexed 
killing might be important (Figure 3A and Movie M4). The frequency of simultaneous 
tumor conjugates that result in tumor cell deaths (46% [43-50%]) was not very different 
from true serial killers that attach, kill, detach and attach to a different tumor cell (49% 
[44-53%]), suggesting that CAR8 cells are capable of eliciting either mode of killing, likely 
dependent on tumor cell density. Individual multi-killer CAR8 cells (Ntotal = 70) 
demonstrated only a small decrease in motility when conjugated to one tumor cell but 
showed no significant change in motility upon conjugation to multiple tumor cells 
(dWell(unconjugated): 5.9±0.5 µm vs dWell (single target): 4.6±0.3 µm vs dWell (two targets): 
4.7±0.3 µm) (Figure 3B). The only difference for multi-killers when contacting the different 
tumor cells was in their time to establish conjugates (tSeek Target1: 18±4 minutes vs Target2: 
98±13 minutes, Figure 3C). Both, duration of conjugation (tContactTarget1: 101±9 minutes 
vs Target2: 113±15 minutes) and killing efficiency (tDeathTarget1: 156± 17 minutes vs 
Target2: 177±24 minutes) were no different (Figure 3D and S13). In addition to contact 
duration, the number of CAR8 cell tumor cell conjugations that lead to killing during 
encounter with the first tumor cells (61% both donors) was also not significantly different 
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from the number of conjugations that resulted in target cell killing during encounter with the 
second tumor cell (74% [70-79 %]). These TIMING data suggest that the efficiency to kill a 
second tumor cell is largely unaffected by the hit on a first target (p-value >0.99). 
Furthermore, in comparison to single killer CAR8 cells, multi-killer CAR8 cells displayed 
greater motility when conjugated to the tumor cell despite the increased crowding because of 
higher tumor cell density, (Figure S14).
Motility can identify a subgroup of CAR4 cells with enhanced cytotoxic efficiency
We have previously reported that the culture of CAR+ T cells in the presence of IL-2 and 
IL-21 on aAPC can lead to outgrowth of CAR4 cells with cytotoxic potential25. In order to 
facilitate comparisons to CAR8 cells, and to demonstrate that CAR4 can directly participate 
in killing and multi-killing (Movie M5), the interaction of individual CAR4 cells from two 
donor-derived populations (Figure 4A), with NALM-6 tumor cells were profiled using 
TIMING. At an E:T ratio of 1:1, 55% (Ntotal = 549) of single CAR4 cells that conjugated to 
a NALM-6 cell subsequently killed the tumor cell. As with the CAR8 cells, the interaction 
behavior of CAR4 cells with the NALM-6 cells could be classified into three subgroups, S1-
S3 (Figure S15). CAR4 cells in the enhanced motility subgroup, S1 (11% both donors), 
displayed significantly faster kinetics of tumor cell death (tDeath 157±17 minutes) compared 
to the dominant S2 (34% [31-36 %]) subgroup (tDeath 318±23 minutes, Figure 4B-D). This 
increased kinetic efficiency was consistent with the decreased conjugation time required by 
the S1 subgroup of cells (tContact 122±11 minutes) in comparison to the S2 subgroup (tContact 
300±21 minutes) (Figure S16). These results suggest that similar to CAR8 cells, the 
motility of the CAR4 cells may help identify the most efficient killers.
Both single-killer and multi-killer CAR4 cells required longer conjugation and 
demonstrated delayed kinetics of killing in comparison to CAR8 cells
At the E:T ratio of 1:1, comparisons of the killing efficiency of CAR4 cells (tDeath 284±11 
minutes) and CAR8 cells (163±12 minutes) demonstrated that individual CAR4 cells on 
average required two extra hours to induce tumor cell death (Figure 4E). Consistent with 
the observation that the S2 subgroup is the dominant population of CAR+ T cells, CAR4 
cells in the S2 subgroup (tDeath 318±23 minutes) demonstrated delayed kinetics of killing in 
comparison to CAR8 cells within the S2 subgroup (tDeath 158±18 minutes) (Figure S17). As 
mentioned above, since the motility of CAR4 cells could be used to identify the most 
efficient killers (Figure 4C), comparisons of the kinetic efficiency of CAR4 cells in the S1 
subgroup (tDeath 157±17 minutes) with CAR8 cells in the S1 subgroup (tDeath 204±34 
minutes) demonstrated no significant differences. This further supports the notion that 
motility might be a useful parameter in identifying efficient cytolytic CAR+ T cells. 
Comparisons of the single-cell behavioral interactions of multi-killer CAR4 cells (Ntotal = 
78) with the CAR8 cells demonstrated that most features were conserved across cells of both 
phenotypes. First, the unconjugated motility of CAR4 cells (dwell 6.9±0.5 µm) was no 
different than CAR8 cells (dwell 5.9±0.5 µm, Figure 5A). Second, like CAR8 cells, CAR4 
cells demonstrated a matched decrease in motility (Figure 5A) and increased circularization 
when conjugated to one or more tumor cells (Figure S18). Third, the preferred contact mode 
of the multi-killer CAR4 cells was also simultaneous conjugations to multiple tumor cells 
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(Figure S19 and Movie M5). Fourth, simultaneous conjugates that result in killing 
accounted for 61% [60-63%] of multi killing events, indicating that this is an important 
mode of killing intrinsic to T cells and not just CD8+ T cells. Fifth, comparisons of tDeath for 
the different tumor cells killed by individual multi-killer CAR4 cells demonstrated no 
differences (Figure 5B). Lastly, the number of CAR4 cell tumor cell conjugations that lead 
to killing during the first tumor cell encounter (60% [58-61 %]) is not significantly different 
from the number of contacts that leads to killing when encountering the second tumor cell 
(60% [57-63 %]), suggesting that the killing efficiency is unchanged. Consistent with the 
observations at an E:T of 1:1, multi-killer CAR4 cells required extended conjugation 
(tContact 214±18 minutes) and demonstrated slower kinetics prior to killing the first tumor 
cell (tDeath 310±23 minutes) in comparison to CAR8 cells (Figure 5B). In aggregate these 
results demonstrate that the major difference in CAR4 cells and CAR8 cells participating in 
either single killing or multi-killing is the kinetics of tumor cell death.
Intracellular GzB content can explain differences in killing efficiency
To test the hypothesis that the varying efficiencies both between cells of the same 
population and in comparing CAR4 cells with CAR8 cells might be due to differences in 
expression of cytotoxic enzymes, we employed intracellular staining at the single-cell level 
using flow cytometry to identify the expression GzB within these cells. To establish baseline 
controls, the intracellular GzB content of CD3+CD4+ cells (2.36±0.01) and CD3+CD8+ cells 
(3.89±0.04) in PBMC of two separate donors was determined (Figure 5C). Consistent with 
our previous reports, both CAR4 cells (38.6±0.2) and CAR8 cells (267±2) showed 
significantly increased expression of GzB, in comparison to the controls (Figure 5C). In 
agreement with the killing efficiency data (Figure 5B), CAR4 cells expressed lower 
amounts of GzB in comparison to CAR8 cells, suggesting that the origin of the differing 
kinetic efficiencies of these cells might be the differences in GzB content (Figure 5C).
In order to quantify the contribution GzB secretion to tumor cell killing at the single cell 
level, the ability of CAR4 cells to kill tumor cells in the presence of the calcium chelator 
EGTA was studied using flow cytometry30. EGTA blocks cytotoxic granule exocytosis, and 
hence should eliminate GzB mediated killing. Not surprisingly, CAR4 cells co-cultured with 
tumor cells in the presence of 5 mM EGTA, demonstrated a substantial reduction in tumor 
cell killing across three different cell lines, Daudi-β2m, NALM-6 and CD19+EL4 (Figure 
5D). The most striking reduction was seen with Daubi-β2m tumor cells, wherein CAR4 cell 
mediated killing was completely abolished (Figure 5D).
CAR+ T-cell fate is dependent on tumor-cell density
AICD is a mechanism by which T cells undergo programmed apoptosis in response to 
functional activation31. The frequency and kinetics of individual cytolytic CAR+ T cells to 
undergo AICD was monitored under the two conditions: at high and low tumor densities. 
CAR8 cells inducing apoptosis of single targets demonstrated significantly faster kinetics of 
AICD (tAICD 221±14 minutes) in comparison to the multi-killer CAR8 cells from the same 
donors (tAICD 371±29 minutes, Figure 6A). This trend of faster AICD kinetics at lower 
tumor cell density was also observed with CAR4 cells, although with delayed kinetics 
(Figure 6A). Direct comparisons of the cells of different phenotypes at the same tumor cell 
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density indicated that single-killer CAR8 cells underwent faster AICD (tAICD, 221±14 
minutes) in comparison to CAR4 cells (t AICD 328±19 minutes) (Figure 6A). Consistent 
with the expectation that multi-killers efficiently resist AICD, these T cells from three of 
four donors displayed low frequencies of cells undergoing AICD (13-25%, Figure 6B). 
However, multi-killer T cells from the last donor displayed AICD at elevated frequencies 
(58%) underscoring that the efficiency of multi-killers to execute multiple tumor cells must 
be evaluated in the context of their ability to resist AICD (Figure 6B). We confirmed that 
the effector apoptosis that was observed required functional antigenic stimulation by co-
incubating CAR8 cells with CD19−EL4 cells within nanowell grids and imaged them using 
TIMING. The frequency of apoptotic effectors under these conditions was only 4% and this 
also confirmed that phototoxicity was negligible under the current imaging conditions.
Significantly, across all four donors, the frequencies of cytolytic CAR+ T cells undergoing 
AICD was higher at an E:T of 1:1 in comparison to the multi-killer CAR+ T cells, and this 
effect was more exaggerated with CAR8 cells (Figure 6B). These data may help account for 
the decrease in number and even disappearance of infused CAR+ T cells when the CD19+ 
tumor mass is reduced.
DISCUSSION
We implemented a high-throughput single-cell assay (TIMING) to dynamically profile the 
functionality of CAR+ T cells. Our analyses at the single-cell level demonstrate that much 
like CAR8 cells, CAR4 cells can directly engage in tumor cell killing, albeit with altered 
kinetics. We further demonstrate that CAR4 cells can participate in multi-killing via 
simultaneous conjugation to multiple tumor cells.
At low tumor cell densities (E:T 1:1), the majority of the single killer CAR8 cells were 
significantly faster in killing tumor cells in comparison to individual CAR4 cells (Figure 
4E). By contrast, both single killer CAR8 and CAR4 cells within the S1 subgroup, 
characterized by their high basal motility, displayed no significant differences in the kinetics 
of tumor cell killing. Furthermore, in contrast to the rest of the population, effector apoptosis 
was infrequent amongst CAR8 and CAR4 cells in the S1 subgroup. Collectively, these data 
suggested that the high basal motility of CAR+ T cells (CAR4 or CAR8) might help identify 
efficient killers with decreased propensity for AICD.
When interacting with increased numbers of tumor cells (E:T ratios of 1:2 to 1:5), both 
individual CAR4 and CAR8 cells efficiently conjugated to multiple tumor cells, facilitating 
multiplexed killing. Comparisons amongst the different tumor cells killed by these 
individual multi-killer CAR4/CAR8 cells demonstrated that they displayed an essentially 
unchanged efficiency (tContact) of killing of not only the first and second target killed, but 
also in comparison to (single-killer) CAR+ T cells that were incubated with only one tumor 
cell (Figure S20). In comparing CAR4 cells with CAR8 cells however, consistent with the 
observations at an E:T ratio of 1:1 , CAR4 cells were significantly slower in tumor cell 
killing. Intracellular staining at the single-cell level indicated that the molecular origin of the 
differences in kinetic efficiency of the CAR4 and CAR8 cells could be attributed to their 
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GzB content and this was further confirmed by blocking granule exocytosis using EGTA 
(Figure 5).
For both CAR4 and CAR8 cells, single killer effectors underwent apoptosis at higher 
frequencies and with faster kinetics in comparison to multi-killer CAR+ T cells (Figures 1 
and 4). These data indicate that activation for lysis through multiple targets as opposed to 
prolonged conjugation with a single target reduces the propensity for effector apoptosis. 
Although the mechanistic basis for the responsiveness of these T cells to antigen/target 
density is not known, it is conceivable that the continuous propagation of these cells on 
irradiated aAPC at defined ratios, allows for balanced activation while minimizing AICD32. 
Collectively, these data could provide mechanistic insights into observations that infused 
CAR+ T cells swell in number in response to addressing large numbers of CD19+ tumor 
cells, but then decline in number as the tumor bioburden is lowered due to the multi-killing 
by effector T cells6,33.
In aggregate, comparisons of the CAR4 cells and CAR8 cells demonstrate that while CAR4 
cells can participate in killing and multi-killing, they do so at slower rates, likely due to the 
lower GzB content. This decreased kinetic efficiency however is likely a minor disadvantage 
and is counter balanced by their decreased propensity of these cells to undergo AICD in the 
absence of help from other cells, as profiled in our nanowell system. Indeed, recent 
preclinical and clinical data have suggested that complete eradication of established tumors 
can be accomplished by the adoptive transfer of T cells derived exclusively from CD4+ T 
cells16-18. Similarly, adoptive transfer of human T helper 17 (TH17) cells has shown 
preclinical promise for the treatment of ovarian cancer34,35. Although we have focused on 
the heterogeneity amongst CAR+ T cells, the results presented here are also likely 
influenced by the underlying heterogeneity in tumor cells. While the expression of CD19 is 
uniform on the cells used as targets in our assays (Figure S4), it is feasible that there could 
be subpopulations of tumor cells that are resistant to CAR+ T-cell mediated killing.
Data from clinical trials have also shown a correlation between in vivo persistence of infused 
CAR+ T cells and patient outcomes36. Significantly, the findings of our short-term TIMING 
data (12h monitoring) that describes motility and ability to resist AICD as important 
attributes of functional T cells, is consistent with persistence data obtained in mouse models 
infusing CD19-specific CAR+ T cells that suggest that these same features are essential for 
tumor regression37. Motility is likely a key parameter of the efficacy of T-cell therapies and 
has a significant role in tumor regression. It has been previously demonstrated that cancer 
cells from B-cell malignancies effectively dampen anti-tumor responses via disruption of 
actin-based basal T-cell motility in vitro38-40. Second, the negative costimulatory molecules, 
PD1 and CTLA4 have opposing effects on T-cell motility both in vitro and in vivo41,42. 
Finally, recent intravital microscopy data from melanoma models in mice have 
demonstrated that successful therapeutic anti-CTLA4 treatment correlates with greater T-
cell motility43.
The variation in the composition of CAR+ T cells within a population of effector cells 
between donors across samples highlights the challenges in eliciting functional 
responsiveness in heterogeneous samples. As the field of adoptive immunotherapy takes on 
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the challenge of targeting diseases that vary in burden, biodistribution, and antigen 
expression and density, it is important that a priori definitions of single-cell potency 
(proliferation, killing, cytokine secretion etc.) be available. We suggest that identifying/
quantifying specific biomarkers of efficacy, as described herein, may enable the 
manufacture of next-generation CAR+ T cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. High-throughput single-cell analysis of CAR+ T-cell cytolytic functionality in nanowell 
grids
(A) Schematic of second-generation CD19-specific CAR (CD19RCD28) that signals 
through chimeric CD28/CD3-ζ. (B) Phenotypic characterization of the CAR+ T cells from 
two separate donors. The total CD3+CAR+ population was gated to reveal the frequencies of 
CD4+ and CD8+ CAR+ T-cell populations. (C) Representative composite micrographs 
illustrating the ability of single CAR+ T cells to kill, and to undergo apoptosis, when 
incubated with tumor cells confined within nanowells. Scale bar 50 µm. (D) Comparison of 
the cytolytic responses measured by the single-cell assay and population-level 51Cr release 
assay, at an E:T ratio of 1:1. The numbers in parentheses for the single-cell assay report the 
total number of events observed. (E) Donut plots summarizing the frequency of killing 
outcomes of the interaction between CAR+ T cells, derived from these two donors, and 
CD19+EL4 target cells. Representative micrographs illustrating each of these interactions 
are shown in Figure S5.
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Figure 2. CAR8 cells can be classified into different subgroups based on their the motility and 
conjugation periods with NALM-6 tumor cell (E:T 1:1)
Schematic depicting the effector parameters used to describe their interaction with single 
NALM-6 tumor cells: (A) Red bar indicates periods of conjugation, blue arrow indicates 
timepoint at which conjugation was first observed, and green line indicates time to target 
death since first conjugation. (B) Aspect ratio of polarization describes the ratio of major 
and minor axis fitted to an ellipse. (C) dWell represents the average displacement of the 
centroid of the effector cell between successive seven minute time points. The mean: (D) 
motility, (E) time to first conjugation, and (F) killing efficiency, of single CAR8 cells in 
each of three different subgroups. Each circle represents a single cell. P-values for multiple 
comparisons were computed using parametric one-way ANOVA.
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Figure 3. Multi-killer CAR8 cells engage in simultaneous conjugations leading to multiplexed 
killing (E:T 1:2-5)
(A) Distribution of the number of simultaneous conjugations of individual CAR8 cells when 
incubated with increasing number of NALM-6 tumor cells. The mean: (B) motility, (C) time 
to first conjugation, and (D) killing efficiency, of individual multi-killer CAR8 cells. P-
values for multiple comparisons were computed using parametric one-way ANOVA.
Liadi et al. Page 16
Cancer Immunol Res. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. Subpopulation of CAR4 cells, identified based on their motility, can engage in efficient 
killing (E:T 1:1)
(A) Phenotypic characterization of the CAR+ T cells from two separate donors that comprise 
of predominantly CD4+CAR+ T cells. The mean: (B) motility, and (C) killing efficiency, of 
single CAR4 cells in each of three different subgroups. (D) Comparison of the means of the 
killing efficiencies between single CAR8 and CAR4 cells within the S1 subgroups. Each 
circle represents a single cell in panels B-D; CAR4 cells are represented using grey circles 
and CAR8 cells are represented using black circles. (E) Comparative Kaplan –Meier 
estimators depicting the differences in killing efficiencies of the entire population of CAR4 
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cells and CAR8 cells. P-values for multiple comparisons (B/C) were computed using a 
parametric one-way ANOVA, and dual comparisons (D/E) computed using unpaired two-
tailed t-test.
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Figure 5. Multi-killer CAR4 cells demonstrated delayed kinetics of killing in comparison to 
CAR8 cells (E:T 1:2-5)
Comparisons between the mean: (A) motility, and (B) killing efficiency, of single multi-
killer CAR8 cells and CAR4 cells. Each circle represents a single cell; CAR4 cells are 
represented using grey circles and CAR8 cells are represented using black circles. (C) Box 
and whisker plots (extremities indicate 99% confidence intervals) displaying intracellular 
expression of Granzyme B identified by immunofluorescent staining and flow-cytometry. 
CAR4 cells (from donors PB5858 and PB333038) and CAR8 cells (from donors PB243566 
and PB281848) were profiled using mAb against CD4/CD8/CAR and GzB. P-values were 
computed using parametric one-way ANOVA for multiple comparisons or t-tests for dual 
comparisons. (D) Flow cytometric killing assay (E:T = 5:1) of CAR4 cells incubated with 
three separate target cell lines (Daudi-β2m, NALM-6 and CD19+EL4) in the absence or 
presence of 5mM EGTA blockade.
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Figure 6. Frequency and kinetics of killer-cell apoptosis are dependent on functional 
conjugations with multiple NALM-6 tumor cells
(A) Comparisons of the mean kinetics of effector apoptosis of individual single killer CAR+ 
T cells (E:T 1:1) with multi-killer CAR+ T cells (E:T 1:2-5). Each circle represents a single-
cell; CAR4 cells are represented using grey circles and CAR8 cells are represented using 
black circles. (B) Frequency of killer-cell apoptosis as a function of tumor cell density.
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